Please login to the form below

Not currently logged in
Email:
Password:

ARK

This page shows the latest ARK news and features for those working in and with pharma, biotech and healthcare.

ROAD wins new account, Ark rebrands and Ashfield sees third intake of writers

ROAD wins new account, Ark rebrands and Ashfield sees third intake of writers

The company is a 15-person strategic agency with over 20 years experience, five of those years has seen ARK BBN become Belgian BBN’s shareholder. ... I think this rebrand shows how powerful this partnership can be and I look forward to witnessing Ark

Latest news

  • IPA’s new training course, Silver Buck launched and ARK moves office IPA’s new training course, Silver Buck launched and ARK moves office

    ARK moves office. Data-driven creative agency ARK has put roots down, opening up a new office based in Covent Garden, London UK.

  • Data-driven creative agency launched Data-driven creative agency launched

    Ark offers consumer-style marketing techniques to deliver campaigns that “demonstrate success with hard metrics”. ... Marchant said: “Ark is the result of six months of investigating what the unmet need is from a clients’ perspective.

  • Regeneron drops RSV drug Regeneron drops RSV drug

    candidates including Johnson &Johnson's lumicitabine which is in phase II testing and hopefuls from Gilead, Aviragen and Ark Bioscience, among others.

  • Emas appoints Dr Neil Murray

    Prior to this he was head of clinical development at Ark Therapeutics and global head of pharmacovigilance at F.Hoffmann-La Roche.

  • MSD invests in FKD Therapies

    MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker. ... FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Ark has in-licensed the global rights to the phase 1. idiopathic pulmonary fibrosis programme. ... Finally, Roche has done a second deal with the China‐based company Ark Biosciences, which specialises in developing treatments for respiratory diseases,

  • Deal Watch January 2016 Deal Watch January 2016

    Instead of being a quiet month, several companies followed the trend noted in the biblical story of Noah's Ark with the animals going in “two by two”; Roche, Sanofi, BMS

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Healthcare Comms appointments Healthcare Comms appointments

    Andrew Martello joins imc, bmore adds to team and ARK gets a new director. ... Kopetka joins Louis Joubert, Nicky King, Seda Marchant and Dom Marchant on the ARK board.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics